Abstract

Primary immune regulatory disorders (PIRD) are associated with autoimmunity, autoinflammation and/or dysregulation of lymphocyte homeostasis. Autoimmune lymphoproliferative syndrome (ALPS) is a PIRD due to an apoptotic defect in Fas-FasL pathway and characterized by benign and chronic lymphoproliferation, autoimmunity and increased risk of lymphoma. Clinical manifestations and typical laboratory biomarkers of ALPS have also been found in patients with a gene defect out of the Fas-FasL pathway (ALPS-like disorders). Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), we identified more than 600 patients suffering from 24 distinct genetic defects described in the literature with an autoimmune lymphoproliferative phenotype (ALPS-like syndromes) corresponding to phenocopies of primary immunodeficiency (PID) (NRAS, KRAS), susceptibility to EBV (MAGT1, PRKCD, XIAP, SH2D1A, RASGRP1, TNFRSF9), antibody deficiency (PIK3CD gain of function (GOF), PIK3R1 loss of function (LOF), CARD11 GOF), regulatory T-cells defects (CTLA4, LRBA, STAT3 GOF, IL2RA, IL2RB, DEF6), combined immunodeficiencies (ITK, STK4), defects in intrinsic and innate immunity and predisposition to infection (STAT1 GOF, IL12RB1) and autoimmunity/autoinflammation (ADA2, TNFAIP3,TPP2, TET2). CTLA4 and LRBA patients correspond around to 50% of total ALPS-like cases. However, only 100% of CTLA4, PRKCD, TET2 and NRAS/KRAS reported patients had an ALPS-like presentation, while the autoimmunity and lymphoproliferation combination resulted rare in other genetic defects. Recurrent infections, skin lesions, enteropathy and malignancy are the most common clinical manifestations. Some approaches available for the immunological study and identification of ALPS-like patients through flow cytometry and ALPS biomarkers are provided in this work. Protein expression assays for NKG2D, XIAP, SAP, CTLA4 and LRBA deficiencies and functional studies of AKT, STAT1 and STAT3 phosphorylation, are showed as useful tests. Patients suspected to suffer from one of these disorders require rapid and correct diagnosis allowing initiation of tailored specific therapeutic strategies and monitoring thereby improving the prognosis and their quality of life.

Highlights

  • Human Inborn Errors of Immunity (IEI), referred to as Primary Immunodeficiencies (PID) are a group of heterogeneous genetic diseases that disrupt the function of the immune system

  • According to the European Society for Immunodeficiencies (ESID), Primary Immune Regulatory Disorders (PIRD) represent approximately 5.3% of IEI and currently comprise 45 diseasecausing genes divided into four categories: hemophagocytic lymphohistiocytosis (HLH), susceptibility to Epstein Barr Virus (EBV), syndromes with autoimmunity and immune dysregulation with colitis [1, 2]

  • The genes in which genetic defects gave rise to an Autoimmune Lymphoproliferative Syndrome (ALPS)-like phenotype, excluding those already described in the Fas-FasL pathway, were selected based on the Immunological Societies (IUIS) classification [1, 2] and a literature search in MEDLINE, Google scholar databases, Web Of Science (WOS) and congress communications

Read more

Summary

Introduction

Human Inborn Errors of Immunity (IEI), referred to as Primary Immunodeficiencies (PID) are a group of heterogeneous genetic diseases that disrupt the function of the immune system. IEI represent more than 400 distinct disorders with more than 430 different gene defects listed in the classical and phenotypical 2019 International Union of Immunological Societies (IUIS) classification [1, 2]. These diseases are mainly monogenic, but increasingly more complex genetic cases such as incomplete penetrance, polygenicity, transcriptional, somatic and epigenetic alterations are being described [3,4,5,6]. Expanded CD3+TcRab+CD4-CD8- double negative T-cells (DNT) are a hallmark of ALPS patients who can present elevated plasma biomarkers including interleukin-10 (IL-10), soluble FasL (sFasL)

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call